1
|
Synthesis and glucose-stimulate insulin secretion (GSIS) evaluation of vindoline derivatives. Bioorg Med Chem Lett 2017; 27:1316-1318. [DOI: 10.1016/j.bmcl.2016.09.064] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2016] [Revised: 09/06/2016] [Accepted: 09/26/2016] [Indexed: 11/20/2022]
|
2
|
Hu L, Song W, Meng Y, Guo D, Liu X, Hu L. Synthesis and structure–activity relationship studies of cytotoxic vinorelbine amide analogues. Bioorg Med Chem Lett 2012; 22:7547-50. [DOI: 10.1016/j.bmcl.2012.10.024] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2012] [Revised: 09/29/2012] [Accepted: 10/04/2012] [Indexed: 10/27/2022]
|
3
|
Song W, Hu L, Meng Y, Ma L, Guo D, Liu X, Hu L. The effect of vindoline C-16 substituents on the biomimetic coupling reaction: Synthesis and cytotoxicity evaluation of the corresponding vinorelbine analogues. Bioorg Med Chem Lett 2012; 22:3485-7. [DOI: 10.1016/j.bmcl.2012.03.082] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2012] [Revised: 03/20/2012] [Accepted: 03/22/2012] [Indexed: 10/28/2022]
|
4
|
June RR, Dougherty DW, Reese CT, Harpster LE, Hoffman SL, Drabick JJ. Significant activity of single agent vinorelbine against small-cell cancer of the bladder as second line chemotherapy: A case series and review of the literature. Urol Oncol 2012; 30:192-5. [DOI: 10.1016/j.urolonc.2009.12.017] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2009] [Revised: 12/19/2009] [Accepted: 12/22/2009] [Indexed: 10/19/2022]
|
5
|
Keating GM, Frampton JE, Moen MD. Vinflunine: a guide to its use in bladder cancer. DRUGS & THERAPY PERSPECTIVES 2012. [DOI: 10.2165/11208720-000000000-00000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
6
|
Song W, Lei M, Zhao K, Hu L, Meng Y, Guo D, Liu X, Hu L. Ceric ammonium nitrate-promoted oxidative coupling reaction for the synthesis and evaluation of a series of anti-tumor amide anhydrovinblastine analogs. Bioorg Med Chem Lett 2011; 22:387-90. [PMID: 22115594 DOI: 10.1016/j.bmcl.2011.10.114] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2011] [Revised: 10/26/2011] [Accepted: 10/31/2011] [Indexed: 10/15/2022]
Abstract
A new, practical and efficient method for the synthesis of anhydrovinblastine AVBL (1f) by oxidative coupling of vindoline and catharanthine in the presence of ceric ammonium nitrate (CAN) was developed. Under the optimized reaction conditions, we synthesized a new series of amide anhydrovinblastine analogs substituted at the vindoline moiety of C-23 site and, evaluated for their proliferation inhibition against HeLa cell. The aryl-substituted derivatives showed loss of potency, while alkyl-substituted derivatives retained some of its cytotoxic potency. The iso-butylamide compound 10b and 2-furancorboxamide compound 18b displayed a similar cytotoxic potency compared to the positive control AVBL.
Collapse
Affiliation(s)
- Weibin Song
- School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, PR China
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Lopez C, Claude B, Morin P, Pelissou M, Pena R, Max JP, Ribet JP. Synthesis and study of a molecularly imprinted polymer for specific solid-phase extraction of vinflunine and its metabolite from biological fluids. J Sep Sci 2011; 34:1902-9. [DOI: 10.1002/jssc.201100015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2011] [Revised: 05/13/2011] [Accepted: 05/15/2011] [Indexed: 11/11/2022]
|
8
|
Mamtani R, Vaughn DJ. Vinflunine in the treatment of advanced bladder cancer. Expert Rev Anticancer Ther 2011; 11:13-20. [PMID: 21166506 DOI: 10.1586/era.10.196] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Accounting for 14,000 deaths in the USA last year, research informs us that advanced bladder cancer is a lethal disease with a median survival that has remained a little over 1 year for the past two decades. For the majority of patients with metastatic disease, chemotherapy with cisplatin-based combinations is the standard first-line treatment. Although initial response rates are high, disease progression is common, creating a growing number of patients in need of effective second-line chemotherapy. For this population, no standard of care currently exists. Salvage chemotherapy is associated with low response rates and studies exploring potential clinical benefit over supportive care alone are limited to nonrandomized Phase II trials. Vinflunine, a novel anti-mitotic drug from the Vinca alkaloid class, is the first and only agent that has been compared with supportive care in the second-line setting. In Europe, vinflunine is approved as a treatment option for patients with advanced urothelial cancer who have failed a prior platinum-containing regimen. To date, in the USA, there is no FDA-approved second-line chemotherapy for patients with metastatic bladder cancer and treatment continues to emphasize patient enrollment into a clinical trial.
Collapse
Affiliation(s)
- Ronac Mamtani
- Abramson Cancer Center of the University of Pennsylvania, 16 Penn Tower, 34th and Civic Center Boulevard, Philadelphia, PA 19104, USA
| | | |
Collapse
|
9
|
&NA;. Vinflunine: a guide to its use in bladder cancer. DRUGS & THERAPY PERSPECTIVES 2010. [DOI: 10.2165/11206130-000000000-00000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
10
|
|
11
|
Yardley DA, McCleod M, Schreiber F, Murphy P, Patton J, Thompson DS, Shastry M, Rubin M, Melnik M, Burris HA, Hainsworth JD. A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer. Cancer Invest 2010; 28:925-31. [DOI: 10.3109/07357907.2010.496755] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
12
|
|
13
|
|
14
|
Retz M, Gschwend JE, Lehmann J. [Systemic chemotherapy for bladder cancer: news in 2009]. Urologe A 2009; 48:655-62. [PMID: 19557469 DOI: 10.1007/s00120-009-2021-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
This review summarizes the results of first-line and second-line systemic chemotherapy for advanced urothelial carcinoma as well as data from adjuvant and neoadjuvant trials for locally advanced bladder cancer. Whereas conventional systemic chemotherapy prevailed for over two decades, targeted therapeutics have been introduced to treat urothelial cancer during recent years. As in other tumor entities, molecular profiling will presumably emerge in the future as a means to tailor individual therapy.
Collapse
Affiliation(s)
- M Retz
- Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität, München, Deutschland.
| | | | | |
Collapse
|
15
|
Ready for a comeback of natural products in oncology. Biochem Pharmacol 2008; 77:1447-57. [PMID: 19161987 DOI: 10.1016/j.bcp.2008.12.013] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2008] [Revised: 11/30/2008] [Accepted: 12/09/2008] [Indexed: 01/26/2023]
Abstract
Since the late 1990s and the rapid expansion of monoclonal antibodies and synthetic protein kinase inhibitors in oncology, anticancer natural products fell out of fashion with the pharmaceutical industry. But in 2007 with the approval of three new drugs derived from natural products, the emergence of promising antitumor compounds from microorganisms (e.g. alvespimycin, salinosporamide) and the growing importance of new formulations of known natural product-derived drugs (nanoparticle formulations, oral forms), we are witnessing a new wave for natural products in oncology. The recent approval of the microtubule-targeted epothilone derivative ixabepilone (Ixempra), the DNA-alkylating marine alkaloid trabectedin (Yondelis) and the inhibitor of mTOR protein kinase temsirolimus (Torisel) is emblematic of the evolution of the field which combines the long established finding of conventional cytotoxic agents and the emergence of molecularly targeted therapeutics. These three examples also illustrate the increasing importance of microbial sources for the discovery of medically useful natural products. The contribution of innovative biological targets is also highlighted here, with references to proteasome inhibitors and novel approaches such as manipulation of mRNA splicing. Altogether, these observations plead for the return of natural products in oncology.
Collapse
|
16
|
Voss ME, Ralph JM, Xie D, Manning DD, Chen X, Frank AJ, Leyhane AJ, Liu L, Stevens JM, Budde C, Surman MD, Friedrich T, Peace D, Scott IL, Wolf M, Johnson R. Synthesis and SAR of vinca alkaloid analogues. Bioorg Med Chem Lett 2008; 19:1245-9. [PMID: 19147348 DOI: 10.1016/j.bmcl.2008.12.077] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2008] [Revised: 12/16/2008] [Accepted: 12/17/2008] [Indexed: 10/21/2022]
Abstract
Versatile intermediates 12'-iodovinblastine, 12'-iodovincristine and 11'-iodovinorelbine were utilized as substrates for transition metal based chemistry which led to the preparation of novel analogues of the vinca alkaloids. The synthesis of key iodo intermediates, their transformation into final products, and the SAR based upon HeLa and MCF-7 cell toxicity assays is presented. Selected analogues 27 and 36 show promising anticancer activity in the P388 murine leukemia model.
Collapse
Affiliation(s)
- Matthew E Voss
- Albany Molecular Research, Inc., 26 Corporate Circle, PO Box 15098, Albany, NY 12212-5098, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
Vinflunine (VFL) is a third-generation bifluorinated semi-synthetic vinca alkaloid obtained by superacidic chemistry from its parent compound, vinorelbine. As with the other vinca alkaloids, the main antineoplastic effects of VFL arise from its interaction with tubulin, the major component of microtubules in mitotic spindles. In contrast to other vinca alkaloids, VFL shows some distinctive properties in terms of tubulin binding, possibly explaining its superior antitumor activity in vitro and in vivo compared with vinorelbine as well as its excellent safety profile. In transitional cell carcinoma (TCC), two single-agent phase II trials were performed testing VFL in platinum-pretreated patients, showing moderate response rates and promising disease control rates. Therefore, the first phase III trial in modern times for second-line TCC of the urothelium was designed in order to further investigate the activity of VFL. First results were presented at the 2008 ASCO conference. VFL appears to be a possible treatment option for patients with TCC progressing after first-line platinum-containing chemotherapy.
Collapse
Affiliation(s)
- Mark Bachner
- 3rd Medical Department - Center for Oncology and Hematology, Kaiser Franz Josef-Spital der Stadt Wien, and Ludwig Boltzmann-Institute for Applied Cancer Research Vienna (LBI-ACR VIEnna), Cluster Translational Oncology, Kaiser Franz Josef-Spital der Stadt Wien, and Applied Cancer Research - Institution for Translational Research Vienna (ACR-ITR VIEnna)/CEADDP, Vienna, Austria.
| | | |
Collapse
|